Systematic review with meta‐analysis: the risk of major gastrointestinal bleeding with non‐vitamin K antagonist oral anticoagulants

By  

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, Vol. 42, Iss. 11-12, 2015-12 ,pp. : 1239-1249

John Wiley & Sons Inc

Access to resources Recommend Favorite

Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 6, 2015-06 ,pp. : 1019-1027

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical impact and course of major bleeding with rivaroxaban and vitamin K antagonists

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 9, 2015-09 ,pp. : 1590-1596

John Wiley & Sons Inc

Access to resources Recommend Favorite

Editorial [Abnormal Bleeding or Bruising Associated with Antiepileptic Treatment]

By  

Current Drug Safety, Vol. 4, Iss. 3, 2009-09 ,pp. : 167-168

Bentham Science Publishers

Access to resources Recommend Favorite

Comparison of Treatment Persistence with Dabigatran or Rivaroxaban versus Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients: A Competing Risk Analysis in the French National Health Care Databases

By  

PHARMACOTHERAPY: THE JOURNAL OF HUMAN PHARMACOLOGY AND DRUG THERAPY, Vol. 38, Iss. 1, 2018-01 ,pp. : 6-18

John Wiley & Sons Inc

Access to resources Recommend Favorite